Ravi Srinivasan Email & Phone Number

Us

ABOUT CAGE BIO INC.►Clinical stage biotech developing first-in-class therapeutics for leading dermatological conditions ►Novel Ionic Liquid platform enabling transdermal delivery of challenging small molecules, biologics, aptamers ►Developing products for rosacea, atopic dermatitis, alopecia indicationsPARTNERSHIP►Partnership with Nitto-Denko

Cambridge, Massachusetts, Us

ABOUT i2o THERAPEUTICS INC.► Harvard spinout, developing first-in-class ionic-liquid based oral biologic products for major indications such as obesity (oral GLP1 and related incretins), diabetes, IBD►i2o is focused on creating the next generation of oral peptide and protein-based therapies►Funded by Morningside Ventures, Sanofi Ventures, JDRF, Touchdown, Viva, 7G, HM Capital and Colorcon Ventures ►Ongoing collaborations with Sanofi on oral nanobodies, Janseen on oral macromolecules, and with Colorcon on small molecules►Using an innovative ionic liquid technology, this platform leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across GI cell wall.CO-FOUNDER►Founded i2o Therapeutics in March 2019CEO►Joined as the CEO of i2o Therapeutics in March 2021ACHIEVEMENTS► Established 2 pharma partnerships in 9 months of company creation►Raised Capital from Marquee Investors►Recruited stellar team, board, SAB►In-licensed best-in-class GLP1 and incretin proprietary peptide pharma assets ►Business Plan Development►Drug Pipeline Buildout ($20B+ market targeting obesity via oral GLP1 and combination incretin peptides)►Established broad IP estate

FOUNDER►Founded and led company from lab bench university technology through Phase 2 clinical trials (with FDA fast track designation)RAISED CAPITAL ►Raised over $80MM+ in financingCOLLABORATIONS►Established two big pharma research collaborationsTHOUGHT-LEADER RECRUITMENT►Built marquee leadership and thought leader team ►Recruited Professor Charles Balch (ex-CEO ASCO, President MD Anderson) & Professor John Niederhuber (ex-head NCI, Chair of Surgery at Stanford and Johns Hopkins) to the SAB PRODUCT PIPELINE►Developed product pipeline of therapeutic and imaging products►Products deliver solutions across continuum of cancer care from early PET detection, intra-operative tumor imaging for surgery, therapeutic drugs (cytokines, STING agonists)►Technology platform exploits pH dysregulation in cancers- well established cancer hallmark► Ability to delivery small molecule, imaging, protein and peptide payloads to tumors and lymph nodesCLINICAL TRIALS►Lead product in Phase 2 trials with excellent safety and efficacy profile (100% patient response in 30 patients across 4 different tumors- breast, colorectal, esophegeal, head-and-neck; no SAEs)►Clinical Trials were conducted with Thought Leader PIs at leading cancer centers: Chairs of Surgery and Chair of Breast Cancer Surgery @ MD Anderson; Chair of Breast Surgery @ U Penn; Chair of Surgery @ UTSW;

ABOUT S.E.A. MEDICAL►Studies have shown IV administration error rate of up to 40% and causes over 7000 deaths in the US►S.E.A. Medical develops products to detect the drug composition, concentration and dose for use in several points in the drug chain from pharmacy to patient bedside IV-line to address this serious patient safety unmet medical needARTIFICIAL INTELLIGENCE (AI)►Built AI and Mission Learning Tools to enable drug identification R&D TEAM ►Led R&D team to develop products based on machine learning and novel sensors to prevent hospital drug medication errorsCOLLABORATION ►Managed a collaboration with Becton Dickinson

FOUNDER ►Founded the company to develop novel oncology small molecule drugs targeting key cancer stem cell and metabolism pathwaysABOUT STEMPAR SCIENCES INC.►The company was based on the collected scientific works of Prof. Sendurai Mani at MD Anderson cancer center (and MIT-Whitehead Institute), Prof. David Boothman and Prof. Jinming Gao at UT SouthWestern Medical Center, and Prof. Paul Hergenrother at the University of Illinois at Urbana

Boston, Ma, Us

ABOUT CORIUM►Corium is an established trans-dermal drug delivery company with two FDA approved and three commercial products►Acquired by Gurnet Point ($500MM)SCOPE►Member of executive management team and board►Overall company strategy, planning, execution►Part of executive team that raised over $60MM in equity financingMICROJET►Co-head of Microjet drug delivery platform►Led the engineering and product development

Us

ABOUT STRATAGENT LIFE SCIENCES►StrataGent Life Sciences developed a wearable "patch-pump" for delivering injectables such as insulin painlessly via the skinAWARDS►The product won the Edison award in the category of Medical Device Game ChangerTECHNICAL CO-FOUNDER►Led engineering and product development activities►Identified the market need and conceived of the product concept with other co-founders►In-licensed technology from Stanford University ►Miniaturized university prototype from desktop unit powered from mains, to wearable portable battery powered unitRAISED CAPITAL ►Raised over $20MM equity financingMERGER►Merged the company with Corium, an established transdermal company

Doctor Of Philosophy (Phd), Chemical Engineering

B.Tech., Chemical Engineering

Doctor Of Philosophy - Phd, Engineering